Trial · NCT02539225
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Ramucirumab + S-1 + Oxaliplatin | 6.34 | 80% Confidence Interval 5.65 to 6.93 | Months | |
| Progression Free Survival (PFS) | Placebo + S-1 + Oxaliplatin | 6.74 | 80% Confidence Interval 5.75 to 7.13 | Months | |
| Progression-free Survival to the Second Disease Progression (PFS 2) | Ramucirumab + S-1 + Oxaliplatin | 10.94 | 80% Confidence Interval 9.63 to 12.52 | Months | |
| Progression-free Survival to the Second Disease Progression (PFS 2) | Placebo + S-1 + Oxaliplatin | 11.99 | 80% Confidence Interval 9.82 to 13.83 | Months | |
| Overall Survival (OS) | Ramucirumab + S-1 + Oxaliplatin | 14.65 | 80% Confidence Interval 12.39 to 15.67 | Months | |
| Overall Survival (OS) | Placebo + S-1 + Oxaliplatin | 14.26 | 80% Confidence Interval 13.83 to 17.31 | Months | |
| Percentage of Participants With Objective Response Rate (ORR) | Ramucirumab + S-1 + Oxaliplatin | 58.2 | 80% Confidence Interval 49.7 to 66.7 | percentage of participants | |
| Percentage of Participants With Objective Response Rate (ORR) | Placebo + S-1 + Oxaliplatin | 50.0 | 80% Confidence Interval 41.3 to 58.7 | percentage of participants | |
| Disease Control Rate (DCR) | Ramucirumab + S-1 + Oxaliplatin | 90.9 | 80% Confidence Interval 85.9 to 95.9 | percentage of participants | |
| Disease Control Rate (DCR) | Placebo + S-1 + Oxaliplatin | 87 | 80% Confidence Interval 81.2 to 92.9 | percentage of participants | |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A | Ramucirumab + S-1 + Oxaliplatin - Part A | Cycle 1 Day 1 | NA | Geometric Coefficient of Variation NA | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A | Ramucirumab + S-1 + Oxaliplatin - Part A | Cycle 1 Day 8 | 42.6 | Geometric Coefficient of Variation 32 | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A | Ramucirumab + S-1 + Oxaliplatin - Part A | Cycle 2 Day 1 | 41.4 | Geometric Coefficient of Variation 40 | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A | Ramucirumab + S-1 + Oxaliplatin - Part A | Cycle 3 Day 1 | 59.4 | Geometric Coefficient of Variation 51 | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A | Ramucirumab + S-1 + Oxaliplatin - Part A | Cycle 5 Day 1 | 83.6 | Geometric Coefficient of Variation 37 | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A | Ramucirumab + S-1 + Oxaliplatin - Part A | Cycle 9 Day 1 | 94.6 | Geometric Coefficient of Variation 38 | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B | Ramucirumab + S-1 + Oxaliplatin Part B | Cycle 1 Day 1 | 52.0 | Geometric Coefficient of Variation 65 | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B | Placebo + S-1 + Oxaliplatin - Part B | Cycle 1 Day 1 | NA | Geometric Coefficient of Variation NA | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B | Ramucirumab + S-1 + Oxaliplatin Part B | Cycle 2 Day 1 | 58.1 | Geometric Coefficient of Variation 40 | Microgram per milliliter (ug/mL) |
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B | Placebo + S-1 + Oxaliplatin - Part B | Cycle 2 Day 1 | 41.0 | Geometric Coefficient of Variation 45 | Microgram per milliliter (ug/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02539225/results